58.7  -0.1 (-0.17%)		01-22 16:00
Open: 58.86 High: 58.99 Volume: 20,956,839		Pre. Close: 58.8 Low: 58.54 Market Cap: 4,118(M)

Short term
Mid term
Targets	6-month :	69.44	1-year :	81.11
Resists	First :	59.45	Second :	69.44
Pivot price	58.93
Supports	First :	58.07	Second :	57.22
MAs	MA(5) :	58.77	MA(20) :	58.92
	MA(100) :	52.37	MA(250) :	45.4
MACD	MACD :	0.3	Signal :	0.4
%K %D	K(14,3) :	19.3	D(3) :	22.7
RSI	RSI(14): 56.1
52-week	High :	64.41	Low :	27.29

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MRTX ] has closed above bottom band by 11.5%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	58.84 - 59.23	59.23 - 59.58
Low:	57.71 - 58.22	58.22 - 58.68
Close:	57.93 - 58.72	58.72 - 59.43

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Thu, 11 Jan 2024
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC - Yahoo Finance

Wed, 10 Jan 2024
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - PR Newswire

Mon, 25 Dec 2023
Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition - Seeking Alpha

Mon, 06 Nov 2023
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates - PR Newswire

Fri, 03 Nov 2023
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - PR Newswire

Mon, 09 Oct 2023
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal - Reuters

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	70 (M)
Held by Insiders	3.891e+007 (%)
Held by Institutions	1.7 (%)
Shares Short	4,740 (K)
Shares Short P.Month	0 (K)

EPS	-7.6068e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	49.1 %
Return on Equity (ttm)	-39.3 %
Qtrly Rev. Growth	3.819e+007 %
Gross Profit (p.s.)	262.33
Sales Per Share	-90.85
EBITDA (p.s.)	0
Qtrly Earnings Growth	-12.2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-594 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.65
Price to Cash Flow	3.34

Dividend	0
Forward Dividend	4.39e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.